Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Share-based Compensation (2024 - 2025)

Prelude Therapeutics' Share-based Compensation history spans 2 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 51.14% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $11.9 million, down 44.19%, while the annual FY2025 figure was $11.9 million, 44.19% down from the prior year.
  • Share-based Compensation for Q4 2025 was $1.8 million at Prelude Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.1 million in Q2 2024 and bottomed at $1.8 million in Q4 2025.